Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement

Autor(es)

Batista-Duharte, Alexander ^{[1, 2]} ; Sendra, Luis ^[2] ; Herrero, Maria Jose ^[2] ; Tellez-Martinez, Damiana ^[1] ; Carlos, Iracilda Zeppone ^[1] ; Alino, Salvador Francisco ^[2]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Dept Clin Anal, Sch Pharmaceut Sci, Rod Araraquara Jau Km 1, BR-14800903 Araraquara, SP - Brazil

^[2] Univ Valencia, Fac Med, Pharmacol Dept, Av Blasco Ibanez 15, Valencia 46010 - Spain

• Tipo de documento: Artigo de Revisão
• Fonte: BIOMOLECULES; v. 10, n. 2 FEB 2020.
• Citações Web of Science: 1

Resumo

Antisense oligonucleotides (ASOs) are synthetically prepared short single-stranded deoxynucleotide sequences that have been validated as therapeutic agents and as a valuable tool in molecular driving biology. ASOs can block the expression of specific target genes via complementary hybridization to mRNA. Due to their high specificity and well-known mechanism of action, there has been a growing interest in using them for improving vaccine efficacy. Several studies have shown that ASOs can improve the efficacy of vaccines either by inducing antigen modification such as enhanced expression of immunogenic molecules or by targeting certain components of the host immune system to achieve the desired immune response. However, despite their extended use, some problems such as insufficient stability and low cellular delivery have not been sufficiently resolved to achieve effective and safe ASO-based vaccines. In this review, we analyze the molecular bases and the research that has been conducted to demonstrate the potential use of ASOs in vaccines. (AU)

• Processo FAPESP: 18/15187-2 - Efeito do silenciamento de Foxp3 na inmunogenicidade de vacinas contra Sporothrix schenckii
• Beneficiário: Alexander Batista Duharte
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Pós-Doutorado